Overview

This clinical trial studies how well 3-dimensional multi-parametric ultrasound (3D MPUS) imaging works as a decision-support tool for patients with liver tumors undergoing therapy. Continuous and dynamic imaging of patients undergoing therapy is required to monitor early-phase treatment response. 3D-MPUS is an inexpensive and safe method, which may provide complementary quantitative functional (perfusion) and tissue characterization information to anatomical radiological assessment or blood biomarkers.

Eligibility

Inclusion Criteria:

1. The participant is about to undergo a new course of therapy for primary or metastatic liver cancer.
2. The participant is age > 18 years.
3. Participant has at least one target lesion (≥1cm and <14cm)
4. The participant is willing to comply with protocol requirements.
5. The participant has the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1. Participant has documented anaphylactic or other severe reactions to any ultrasound or CT contrast media.
2. Participant has documented severe Hypersensitivity to macrogol/ polyethylene glycol (PEG).
3. Participant has documented the presence of a cardiac shunt or pulmonary hypertension (pulmonary artery pressure >90 mmHg).
4. Participant has documented renal insufficiency with a creatinine level of >1.5mg/dl.
5. Participant has documented uncontrolled systemic hypertension.
6. Participant has documented concomitant diseases like acute endocarditis, prosthetic valve, hyperactive coagulation states and/ or recent thromboembolism, and sepsis
7. Participant is pregnant (positive urine or serum beta-hCG) or lactating.